These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1488 related articles for article (PubMed ID: 7808487)
1. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Zittoun RA; Mandelli F; Willemze R; de Witte T; Labar B; Resegotti L; Leoni F; Damasio E; Visani G; Papa G N Engl J Med; 1995 Jan; 332(4):217-23. PubMed ID: 7808487 [TBL] [Abstract][Full Text] [Related]
3. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. Cassileth PA; Harrington DP; Appelbaum FR; Lazarus HM; Rowe JM; Paietta E; Willman C; Hurd DD; Bennett JM; Blume KG; Head DR; Wiernik PH N Engl J Med; 1998 Dec; 339(23):1649-56. PubMed ID: 9834301 [TBL] [Abstract][Full Text] [Related]
4. [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group]. Hübner G; Link H; Schönrock-Nabulsi P; Wandt H; Gramatzki M; Löffler B; Fackler-Schwalbe I; Queisser W; Brack N; Geer T; Raab M; Ohl S; Schneider B; Schneider C; Freund M; Poliwoda H; Ehninger G Med Klin (Munich); 1996 Apr; 91 Suppl 3():26-32. PubMed ID: 8692115 [TBL] [Abstract][Full Text] [Related]
5. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups. Keating S; Suciu S; de Witte T; Mandelli F; Willemze R; Resegotti L; Broccia G; Thaler J; Labar B; Damasio E; Bizzi B; Rotoli B; Vekhoff A; Muus P; Petti MC; Dardenne M; Solbu G; Vegna ML; Zittoun RA Bone Marrow Transplant; 1996 Jun; 17(6):993-1001. PubMed ID: 8807105 [TBL] [Abstract][Full Text] [Related]
6. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia. Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868 [TBL] [Abstract][Full Text] [Related]
7. Allogeneic versus autologous bone marrow transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML8 A). The EORTC Leukemia Cooperative Group and the GIMEMA Group. Zittoun R; Mandelli F; Willemze R; de Witte T; Tura S; Ferrini PR; Stryckmans P; Gattringer C; Petti MC; Solbu G Leukemia; 1992; 6 Suppl 2():114-5. PubMed ID: 1578909 [No Abstract] [Full Text] [Related]
8. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Michel G; Leverger G; Leblanc T; Nelken B; Baruchel A; Landman-Parker J; Thuret I; Bergeron C; Bordigoni P; Esperou-Bourdeau H; Perel Y; Vannier JP; Schaison G Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165 [TBL] [Abstract][Full Text] [Related]
9. Long-term results in non randomized patients with acute myelogenous leukemia: a single institution experience. Deliliers GL; Annaloro C; Oriani A; Della Volpe A; Boschetti C; Cortelezzi A; Maiolo AT Ann Ital Med Int; 1998; 13(3):146-51. PubMed ID: 9859570 [TBL] [Abstract][Full Text] [Related]
10. [Comparison between intensive consolidation by bone marrow autograft or by chemotherapy of acute myeloblastic leukemias in 1st complete remission: AML8A protocol of the Leukemia Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC)]. Zittoun R; Rio B; Delmer A; Vekhof A; Mandelli F; Willemze R; de Witte T; Tura S; Ferrini PR; Stryckmans P Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):15-6. PubMed ID: 8511034 [No Abstract] [Full Text] [Related]
11. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. Tallman MS; Pérez WS; Lazarus HM; Gale RP; Maziarz RT; Rowe JM; Marks DI; Cahn JY; Bashey A; Bishop MR; Christiansen N; Frankel SR; García JJ; Ilhan O; Laughlin MJ; Liesveld J; Linker C; Litzow MR; Luger S; McCarthy PL; Milone GA; Pavlovsky S; Phillips GL; Russell JA; Saez RA; Schiller G; Sierra J; Weiner RS; Zander AR; Zhang MJ; Keating A; Weisdorf DJ; Horowitz MM Biol Blood Marrow Transplant; 2006 Feb; 12(2):204-16. PubMed ID: 16443518 [TBL] [Abstract][Full Text] [Related]
12. Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment. Shin HJ; Kim HJ; Sohn SK; Min YH; Won JH; Kim I; Yoon HJ; Lee JH; Jo DY; Joo YD; Jung CW; Lee KH; ; Chung JS; Ahn JS; Kim SJ; Lee JH; Choi SJ; Lee JH; Bae SH; Hong DS; Zang DY; Kim SH; Lee JL; Bang SM Jpn J Clin Oncol; 2010 Jun; 40(6):556-66. PubMed ID: 20185460 [TBL] [Abstract][Full Text] [Related]
13. Allogeneic versus autologous bone marrow transplantation versus chemotherapy for treatment of acute myeloid leukemia in first complete remission (BGM 84 and BGMT 87 studies). The BGMT Group. Reiffers J; Stoppa AM; Rigal-Huguet F; Michallet M; Marit G; Gastaut JA; Attal M; Corront B; Broustet A; Hollard D Bone Marrow Transplant; 1991; 7 Suppl 2():36. PubMed ID: 1878709 [No Abstract] [Full Text] [Related]
14. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. Mayer RJ; Davis RB; Schiffer CA; Berg DT; Powell BL; Schulman P; Omura GA; Moore JO; McIntyre OR; Frei E N Engl J Med; 1994 Oct; 331(14):896-903. PubMed ID: 8078551 [TBL] [Abstract][Full Text] [Related]
15. Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy. Brunet S; Esteve J; Berlanga J; Ribera JM; Bueno J; Martí JM; Bargay J; Guardia R; Juliá A; Granena A; Montserrat E; Sierra J; Haematologica; 2004 Aug; 89(8):940-9. PubMed ID: 15339677 [TBL] [Abstract][Full Text] [Related]
17. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells. Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929 [TBL] [Abstract][Full Text] [Related]
18. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266 [TBL] [Abstract][Full Text] [Related]
19. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children]. Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900 [TBL] [Abstract][Full Text] [Related]
20. BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. Meloni G; Vignetti M; Avvisati G; Capria S; Micozzi A; Giona F; Mandelli F Bone Marrow Transplant; 1996 Oct; 18(4):693-8. PubMed ID: 8899182 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]